In Ras/MAPK mutant cancers, a conserved gene signature that includes ETV4/5, SPRY2/4, DUSP4/6, and EPHA2/4 is a reliable biomarker of pathway activation and is associated with good clinical response to MEK inhibitor therapy66. Here, SPRY2 is linked to cancer.